<DOC>
	<DOC>NCT01871493</DOC>
	<brief_summary>The main purpose of this study is to evaluate how the body absorbs and removes LY2605541, insulin lispro, and a mixture of both from the blood. The study has two parts. Participants may enroll in only one part. Each part has four treatment periods in a fixed order. The study will last approximately 8 weeks, not including screening. Screening is required within 28 days prior to the start of the study.</brief_summary>
	<brief_title>A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Are not of childbearing potential Have a body mass index (BMI) between 18 and 29.9 kilograms per meter squared (kg/m^2), inclusive Are nonsmokers or have not smoked for at least 2 months prior to entering the study Have known allergies to insulin or its excipients, or related drugs, or history of relevant allergic reactions of any origin Have a history of firstdegree relatives known to have diabetes mellitus Have used systemic glucocorticoids within 3 months prior to entry into the study Have donated blood or had a blood loss of 450 milliliter (mL) within 1 month prior to study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>